Literature DB >> 11782349

Systemic tumor suppression by the proapoptotic gene bik.

Yiyu Zou1, Hua Peng, Binhua Zhou, Yong Wen, Shao-Chun Wang, Eing-Mei Tsai, Mien-Chie Hung.   

Abstract

Metastatic breast cancer requires systemic treatment. We have developed a systemic gene therapy approach for breast cancer, consisting of a nonviral gene delivery system (SN) and a proapoptotic gene, bik. The transfection efficiency of SN carrying a reporter gene was 5-10 times higher than the common nonviral agents Fugene-6 and Lipofectamine in the presence of serum. The SN-bik gene complex induced significant apoptosis in four breast cancer cell lines in vitro as well as in orthotopic tumor tissues in nude mice. Systemically administrated SN-bik significantly inhibited the growth and metastasis of human breast cancer cells implanted in nude mice and prolonged the life span of the treated animals. This study demonstrates that SN-bik is a promising approach for further development as a potential therapeutic agent of cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11782349

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human.

Authors:  Paola Alberici; Emma de Pater; Joana Cardoso; Mieke Bevelander; Lia Molenaar; Jos Jonkers; Riccardo Fodde
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

3.  Proteasome inhibition enhances the killing effect of BikDD gene therapy.

Authors:  Ye Sun; Mariano Ponz-Sarvise; Shih-Shin Chang; Wei-Chao Chang; Chung-Hsuan Chen; Jennifer L Hsu; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

4.  ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Chun-Te Chen; Mo Liu; Chao-Kai Chou; Hong-Jen Lee; Yi Du; Xiaoming Xie; Yongkun Wei; Weiya Xia; Zhang Weihua; Jer-Yen Yang; Chia-Jui Yen; Tzu-Hsuan Huang; Minjia Tan; Gang Xing; Yingming Zhao; Chien-Hsing Lin; Shih-Feng Tsai; Isaiah J Fidler; Mien-Chie Hung
Journal:  Sci Signal       Date:  2010-02-09       Impact factor: 8.192

5.  NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition.

Authors:  Tsutomu Shimazu; Kurt Degenhardt; Alam Nur-E-Kamal; Junjie Zhang; Takeshi Yoshida; Yonglong Zhang; Robin Mathew; Eileen White; Masayori Inouye
Journal:  Genes Dev       Date:  2007-04-02       Impact factor: 11.361

6.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

7.  Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Zhi-Hai Peng; Fang Zhang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

8.  TNFalpha induces HIF-1alpha expression through activation of IKKbeta.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Weiya Xia; Yongkun Wei; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2009-09-17       Impact factor: 3.575

9.  Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.

Authors:  Hsu-Ping Kuo; Dung-Fang Lee; Weiya Xia; Chien-Chen Lai; Long-Yuan Li; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2009-08-28       Impact factor: 3.575

Review 10.  BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes.

Authors:  G Chinnadurai; S Vijayalingam; R Rashmi
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.